Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis
Detection Principle
ImmunoAssay-Antibody
Target
IgG, IgM
Testing Method Category
Testing Method
kit
Testing Method - Additional Info
Point of Care (POC) rapid SARS?CoV?2 IgG?IgM combined antibody test designed by Jiangsu Medomics Medical Technologies, located in Nanjing, China (Lateral flow immunoassay)
Reported Performance
Sensitivity: 88.66%; specificity: 90.63%
Sample Size
397 positive & 128 negative patients
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements